Valuation: Sanofi

Market Cap 92.54B 106B 85.71B 78.86B 149B 10,098B 152B 1,022B 401B 4,959B 396B 388B 17,126B P/E 2026 *
11.6x
P/E 2027 * 10.7x
Enterprise Value 102B 116B 94.63B 87.07B 165B 11,149B 168B 1,128B 442B 5,475B 437B 428B 18,908B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 1.96x
Free-Float
89%
Yield 2026 *
5.52%
Yield 2027 * 5.84%
1 week+0.80%
Current month+2.40%
1 month+0.63%
3 months-4.96%
6 months-9.56%
Current year-8.04%
1 week 74.01
Extreme 74.01
77.3
1 month 71.32
Extreme 71.32
77.61
3 years 71.32
Extreme 71.32
110.84
5 years 71.32
Extreme 71.32
110.84
10 years 62.99
Extreme 62.99
110.84
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%+0.80%-9.05%-18.87% 105B
-0.56%-1.52%+49.04%+171.88% 1,060B
+0.31%-0.60%+64.29%+62.31% 619B
-0.03%-2.65%+28.86%+85.64% 438B
-1.75%-2.91%+28.78%+24.35% 333B
+0.24%-2.61%+29.46%+46.50% 282B
-1.75%-12.77%+20.67%+23.05% 267B
+0.67%-0.76%-26.10%-37.25% 218B
-0.81%-1.63%+22.07%+58.33% 196B
+1.21%+1.38%+19.85%+71.29% 161B
Average -0.23%-2.41%+22.79%+48.72% 397.1B
Weighted average by Cap. -0.28%-2.17%+34.98%+81.14%

Financials

2026 *2027 *
Net sales 46.95B 53.53B 43.49B 40.01B 75.68B 5,124B 77.16B 518B 203B 2,516B 201B 197B 8,689B 50.04B 57.05B 46.34B 42.64B 80.65B 5,460B 82.22B 552B 217B 2,681B 214B 210B 9,260B
Net income 7.99B 9.11B 7.4B 6.81B 12.88B 872B 13.13B 88.2B 34.59B 428B 34.21B 33.46B 1,479B 8.9B 10.15B 8.25B 7.59B 14.35B 972B 14.63B 98.28B 38.54B 477B 38.12B 37.28B 1,648B
Net Debt 9.63B 10.98B 8.92B 8.21B 15.52B 1,051B 15.83B 106B 41.7B 516B 41.23B 40.33B 1,782B 5.52B 6.29B 5.11B 4.7B 8.9B 602B 9.07B 60.93B 23.9B 296B 23.63B 23.11B 1,021B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Date Price Change
26-07-13 €77.06 +0.84%
26-07-10 €76.42 -0.40%
26-07-09 €76.73 +2.31%
26-07-08 €75.00 -0.44%
26-07-07 €75.33 +0.88%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
77.10EUR
Average target price
96.31EUR
Spread / Average Target
+24.92%

Quarterly revenue - Rate of surprise